{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:31:19Z","timestamp":1648567879962},"reference-count":43,"publisher":"Hogrefe Publishing Group","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2019,6]]},"abstract":" Zusammenfassung. Eine Hyperurik\u00e4mie kann zu Gicht f\u00fchren, aber auch das Auftreten weiterer Erkrankungen wie arterielle Hypertonie, Niereninsuffizienz, Diabetes mellitus Typ 2, Myokardinfarkte und Schlaganf\u00e4lle beg\u00fcnstigen. Harns\u00e4ure hat jedoch nicht nur negative Folgen f\u00fcr den K\u00f6rper, sondern scheint auch eine positive Wirkung auf bestimmte degenerative und entz\u00fcndliche neurologische Erkrankungen auszu\u00fcben. Die Entz\u00fcndungsreaktion, die bei einem Gichtanfall auftritt, wird durch IL-1\u03b2 vermittelt. Somit k\u00f6nnen IL-1- oder IL-1-Rezeptor-Antagonisten eingesetzt werden, wenn Kolchizin, Kortikosteroide und NSAR kontraindiziert oder wirkungslos sind. Medikament der ersten Wahl zur langfristigen Senkung des Harns\u00e4urespiegels ist Allopurinol, das auch eine positive Wirkung auf Komorbidit\u00e4ten hat. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003253","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T06:00:23Z","timestamp":1560319223000},"page":"527-533","source":"Crossref","is-referenced-by-count":1,"title":["Licht und Schatten der Hyperurik\u00e4mie: Neuroprotektion, Komorbidit\u00e4ten und Therapiestrategien"],"prefix":"10.1024","volume":"108","author":[{"given":"Heiko","family":"Pohl","sequence":"first","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Innere Medizin, Universit\u00e4tsspital Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Vallelian","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Innere Medizin, Universit\u00e4tsspital Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Herfs","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Innere Medizin, Universit\u00e4tsspital Z\u00fcrich"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","doi-asserted-by":"crossref","unstructured":"Kuo CF, Grainge MJ, Zhang W & Doherty M: Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015; 11: 649\u2013662.","DOI":"10.1038\/nrrheum.2015.91"},{"key":"c2","doi-asserted-by":"crossref","unstructured":"Doherty M, Jansen TL & Nuki G, et al.: Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012; 71: 1765\u20131770.","DOI":"10.1136\/annrheumdis-2012-201687"},{"key":"c3","doi-asserted-by":"crossref","unstructured":"Richette P, Doherty M & Pascual E, et al.: 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29\u201342.","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"c4","doi-asserted-by":"crossref","unstructured":"Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B & Johnson RJ: The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 2013; 99: 759\u2013766.","DOI":"10.1136\/heartjnl-2012-302535"},{"key":"c5","doi-asserted-by":"crossref","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F & Fu P: Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 2014; 15: 122.","DOI":"10.1186\/1471-2369-15-122"},{"key":"c6","doi-asserted-by":"crossref","unstructured":"Kodama S, Saito K & Yachi Y, et al.: Association Between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32: 1737\u20131742.","DOI":"10.2337\/dc09-0288"},{"key":"c7","doi-asserted-by":"crossref","unstructured":"Bos MJ, Koudstaal PJ, Hofman A, Witteman JC & Breteler MM: Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006; 37: 1503\u20131507.","DOI":"10.1161\/01.STR.0000221716.55088.d4"},{"key":"c8","doi-asserted-by":"crossref","unstructured":"Weisskopf M, O\u2019Reilly E, Chen H, Schwarzschild MA & Ascherio A: Plasma urate and risk of Parkinson\u2019s disease. Am J Epidemiol 2007; 166: 561\u2013567.","DOI":"10.1093\/aje\/kwm127"},{"key":"c9","doi-asserted-by":"crossref","unstructured":"Liu B, Shen Y, Xiao K, Tang Y, Cen L & Wei J: Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 2012; 34: 163\u2013171.","DOI":"10.1179\/1743132811Y.0000000074"},{"key":"c10","doi-asserted-by":"crossref","unstructured":"Abraham A & Drory VE: Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 2014; 261: 1133\u20131138.","DOI":"10.1007\/s00415-014-7331-x"},{"key":"c11","doi-asserted-by":"crossref","unstructured":"Kim TS, Pae CU & Yoon SJ, et al.: Decreased plasma antioxidants in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry 2006; 21: 344\u2013348.","DOI":"10.1002\/gps.1469"},{"key":"c12","doi-asserted-by":"crossref","unstructured":"Feig DI, Kang DH & Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811\u20131821.","DOI":"10.1056\/NEJMra0800885"},{"key":"c13","doi-asserted-by":"crossref","unstructured":"Kippen I; et al.: Factors affecting urate solubility in vitro. Annals of the Rheumatic Diseases 1974; 33: 313\u2013317.","DOI":"10.1136\/ard.33.4.313"},{"key":"c14","doi-asserted-by":"crossref","unstructured":"Matzinger P: The danger model: a renewed sense of self. Science 2002; 296: 301\u2013305.","DOI":"10.1126\/science.1071059"},{"key":"c15","doi-asserted-by":"crossref","unstructured":"Rock KL & Kono H: The inflammatory response to cell death. Annu Rev Pathol 2008, 3: 99\u2013126.","DOI":"10.1146\/annurev.pathmechdis.3.121806.151456"},{"key":"c16","doi-asserted-by":"crossref","unstructured":"Rock KL, Kataoka H & Lai JJ: Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 2013; 9: 13\u201323.","DOI":"10.1038\/nrrheum.2012.143"},{"key":"c17","doi-asserted-by":"crossref","unstructured":"Shi Y, Evans JE & Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516\u2013521.","DOI":"10.1038\/nature01991"},{"key":"c18","doi-asserted-by":"crossref","unstructured":"Alvarez-Lario B & Macarron-Vicente J: Uric acid and evolution. Rheumatology (Oxford) 2010; 49: 2010\u20132015.","DOI":"10.1093\/rheumatology\/keq204"},{"key":"c19","doi-asserted-by":"crossref","unstructured":"Ames BN, Cathcart R, Schwiers E & Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858\u20136862.","DOI":"10.1073\/pnas.78.11.6858"},{"key":"c20","doi-asserted-by":"crossref","unstructured":"Kelley EE, Khoo NK, Hundley NJ, Malik UZ, Freeman BA & Tarpey MM: Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radic Biol Med 2010; 48: 493\u2013498.","DOI":"10.1016\/j.freeradbiomed.2009.11.012"},{"key":"c21","doi-asserted-by":"crossref","unstructured":"Schwarzschild MA, Schwid SR & Marek K, et al.: Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008; 65: 716\u2013723.","DOI":"10.1001\/archneur.2008.65.6.nct70003"},{"key":"c22","doi-asserted-by":"crossref","unstructured":"Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M & Ortiz A: Potential dangers of serum urate-lowering therapy. Am J Med 2019; 132: 457\u2013467.","DOI":"10.1016\/j.amjmed.2018.12.010"},{"key":"c23","doi-asserted-by":"crossref","unstructured":"Sanchez-Lozada LG, Tapia E & Santamar\u00eda J, et al.: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237\u2013247.","DOI":"10.1111\/j.1523-1755.2005.00074.x"},{"key":"c24","doi-asserted-by":"crossref","unstructured":"Sharaf El Din\n UAA, Salem MM & Abdulazim DO: Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J Adv Res 2017; 8: 537\u2013548.","DOI":"10.1016\/j.jare.2016.11.004"},{"key":"c25","doi-asserted-by":"crossref","unstructured":"Krishnan E, Akhras KS & Sharma H, et al.: Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM 2013; 106: 721\u2013729.","DOI":"10.1093\/qjmed\/hct093"},{"key":"c26","doi-asserted-by":"crossref","unstructured":"Terkeltaub RA, Schumacher HR & Carter JD, et al.: Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013; 15: R25.","DOI":"10.1186\/ar4159"},{"key":"c27","doi-asserted-by":"crossref","unstructured":"So A, De Meulemeester\n M & Pikhlak A, et al.: Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62: 3064\u20133076.","DOI":"10.1002\/art.27600"},{"key":"c28","doi-asserted-by":"crossref","unstructured":"Schlesinger N, Alten RE & Bardin T, et al.: Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71: 1839\u20131848.","DOI":"10.1136\/annrheumdis-2011-200908"},{"key":"c29","doi-asserted-by":"crossref","unstructured":"Sivera F, Wechalekar MD, Andr\u00e9s M, Buchbinder R & Carmona L: Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev 2014; CD009993.","DOI":"10.1002\/14651858.CD009993.pub2"},{"key":"c30","doi-asserted-by":"crossref","unstructured":"Balasubramaniam G, Parker T & Turner D, et al.: Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study. BMJ Open 2017; 7: e017121.","DOI":"10.1136\/bmjopen-2017-017121"},{"key":"c31","doi-asserted-by":"crossref","unstructured":"So A, De Smedt\n T, Revaz S & Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.","DOI":"10.1186\/ar2143"},{"key":"c32","doi-asserted-by":"crossref","unstructured":"Larsen CM, Faulenbach M, Vaag A, et al.: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517\u20131526.","DOI":"10.1056\/NEJMoa065213"},{"key":"c33","doi-asserted-by":"crossref","unstructured":"Becker MA, MacDonald PA, Hunt BJ, Lademacher C & Joseph-Ridge N: Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008; 27: 585\u2013591.","DOI":"10.1080\/15257770802136032"},{"key":"c34","doi-asserted-by":"crossref","unstructured":"Taylor TH, Mecchella JN, Larson RJ, Kerin KD & Mackenzie TA: Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012; 125: 1126\u20131134e7.","DOI":"10.1016\/j.amjmed.2012.05.025"},{"key":"c35","doi-asserted-by":"crossref","unstructured":"Schlesinger N, Norquist JM & Watson DJ: Serum urate during acute gout. J Rheumatol 2009; 36: 1287\u20131289.","DOI":"10.3899\/jrheum.080938"},{"key":"c36","doi-asserted-by":"crossref","unstructured":"Choi HK, Soriano LC, Zhang Y & Rodr\u00edguez LA: Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344: d8190.","DOI":"10.1136\/bmj.d8190"},{"key":"c37","doi-asserted-by":"crossref","unstructured":"Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ & Choi H: Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 2014; 73: 385\u2013390.","DOI":"10.1136\/annrheumdis-2012-202589"},{"key":"c38","doi-asserted-by":"crossref","unstructured":"Schumacher HR\n Jr, Becker MA & Wortmann RL, et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540\u20131548.","DOI":"10.1002\/art.24209"},{"key":"c39","doi-asserted-by":"crossref","unstructured":"Kanbay M, Huddam B & Azak A, et al.: A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6: 1887\u20131894.","DOI":"10.2215\/CJN.11451210"},{"key":"c40","doi-asserted-by":"crossref","unstructured":"Singh JA, Ramachandaran R, Yu S & Curtis JR: Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord 2017; 17: 76.","DOI":"10.1186\/s12872-017-0513-6"},{"key":"c41","doi-asserted-by":"crossref","unstructured":"White WB, Saag KG & Becker MA, et al.: Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018; 378: 1200\u20131210.","DOI":"10.1056\/NEJMoa1710895"},{"key":"c42","doi-asserted-by":"crossref","unstructured":"Lee JS, Won J & Kwon OC, et al.: Hepatic safety of febuxostat compared with allopurinol in gout patients with fatty liver disease. J Rheumatol 2018; pii: jrheum.180761. doi: 10.3899\/jrheum.180761. [Epub ahead of print].","DOI":"10.3899\/jrheum.180761"},{"key":"c43","doi-asserted-by":"crossref","unstructured":"Chales G: How should we manage asymptomatic hyperuricemia? Joint Bone Spine 2018; pii: S1297\u2013319X(18)30402\u20130. doi: 10.1016\/j.jbspin.2018.10.004. [Epub ahead of print]","DOI":"10.1016\/j.jbspin.2018.10.004"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:15:09Z","timestamp":1615940109000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1024\/1661-8157\/a003253"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003253","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}